Thus, to define the extent of PRMT2 involvement in AML initiation and maintenance, we analyzed PRMT2 expression in 371 patients with de novo AML (excluding acute promyelocytic leukemias) (Fig. 1a) using data from The Leucegene Project (Table 1). This evidence concerns the gene PRMT2 and acute promyelocytic leukemia.